Americans are using more prescription drugs than ever. Consequently, they’re coping with more side effects, drug interactions, and costs, especially if they’re using multiple medications. Kaiser Permanente Washington Health Research Institute (KPWHRI) scientists are on the forefront of answering questions about these concerns. We’re studying the beneficial and harmful effects of medications in real-world settings, and innovating better ways to manage and monitor drug use.
The institute contributes to national initiatives to monitor medication safety as well as providing information to help doctors and patients weigh the risks and benefits of various prescription drugs.
Funders of KPWHRI medication use and patient safety research include the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, the National Institutes of Health, the Patient-Centered Outcomes Research Institute, and other sources. A few projects include:
Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, Rassen JA, Nelson JC, Schneeweiss S. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:32-40. doi: 10.1002/pds.2316. PubMed
Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, Raebel MA, Beaulieu NU, Rosofsky R, Woodworth TS, Brown JS. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:23-31. doi: 10.1002/pds.2336. PubMed
Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:1-8. doi: 10.1002/pds.2343. PubMed
Fireman B, Toh S, Butler MG, Go AS, Joffe HV, Graham DJ, Nelson JC, Daniel GW, Selby JV. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:282-90. doi: 10.1002/pds.2337. PubMed
Cook AJ, Tiwari RC, Wellman RD, Heckbert SR, Li L, Heagerty P, Marsh T, Nelson JC. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:72-81. doi: 10.1002/pds.2320. PubMed
David E. Arterburn, MD, MPHSenior Investigator |
Jennifer F. Bobb, PhDSenior Biostatistics Investigator |
Jessica Chubak, PhDSenior Investigator |
Andrea J. Cook, PhDSenior Biostatistics Investigator |
Maricela Cruz, PhDAssociate Biostatistics Investigator |
Sascha Dublin, MD, PhDSenior Investigator |
Laura Harrington, PhD, MPHAssociate Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Lisa A. Jackson, MD, MPHSenior Investigator |
Rita Mangione-Smith, MD, MPHExecutive Director and Senior Investigator, KPWHRI; Vice President for Research and Health Care Innovation, Kaiser Permanente Washington |
Jess Mogk, MPHCollaborative Scientist |
Jennifer C. Nelson, PhDDirector, Biostatistics; Senior Investigator |
Gaia Pocobelli, PhDSenior Collaborative Scientist |
Susan M. Shortreed, PhDSenior Biostatistics Investigator |
Rod L. Walker, MSPrincipal Collaborative Biostatistician |
Paige D. Wartko, PhD, MPHSenior Collaborative Scientist |
Robert D. Wellman, MSPrincipal Collaborative Biostatistician |
Karen Wernli, PhDSenior Investigator |
Brian D. Williamson, PhDAssociate Biostatistics Investigator |
Onchee Yu, MSPrincipal Collaborative Biostatistician |
Weiwei Zhu, MSPrincipal Collaborative Biostatistician |
Susan Heckbert, MD, PhD
University of Washington (UW) Department of Epidemiology; UW Cardiovascular Health Research Unit
David Siscovick, MD, MPH
UW Department of Medicine; UW Department of Epidemiology; UW Cardiovascular Health Research Unit
Leslie Spangler, PhD
Amgen